Matches in Wikidata for { <http://www.wikidata.org/entity/Q88739962> ?p ?o ?g. }
- Q88739962 description "2018 թվականին հրատարակված գիտական հոդված" @default.
- Q88739962 description "article scientifique (publié 2018)" @default.
- Q88739962 description "articolo scientifico (pubblicato il 2018)" @default.
- Q88739962 description "artigo científico (publicado na 2018)" @default.
- Q88739962 description "artikull shkencor i botuar më 01 janar 2018" @default.
- Q88739962 description "artículo científico publicado en 2018" @default.
- Q88739962 description "artículu científicu espublizáu en xineru de 2018" @default.
- Q88739962 description "im Jahr 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q88739962 description "scientific article published on 01 January 2018" @default.
- Q88739962 description "wetenschappelijk artikel" @default.
- Q88739962 description "наукова стаття, опублікована 1 січня 2018" @default.
- Q88739962 description "научна статия" @default.
- Q88739962 name "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 name "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 name "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 type Item @default.
- Q88739962 label "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 label "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 label "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 prefLabel "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 prefLabel "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 prefLabel "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 P1433 Q88739962-DEC8FF36-9844-46EF-B941-6D5C6C2C133B @default.
- Q88739962 P1476 Q88739962-FF748079-E44C-4257-8865-AA842471FAC7 @default.
- Q88739962 P2093 Q88739962-0D8CB8CC-57E4-48F3-A7DC-BE33F8CC26A3 @default.
- Q88739962 P2093 Q88739962-3BC57153-15FA-4D77-B8AC-50990249000D @default.
- Q88739962 P2093 Q88739962-482BBCF3-7241-4669-88D9-CA2E45D4D575 @default.
- Q88739962 P2093 Q88739962-A8E4D02A-4E87-4612-AB33-0F34AF4A9572 @default.
- Q88739962 P2093 Q88739962-B2EE1457-011C-4970-8824-650B78FD7732 @default.
- Q88739962 P2093 Q88739962-BA736ADF-1701-4E26-B3F9-71B3D6AC7307 @default.
- Q88739962 P2860 Q88739962-04A8DF58-FA2E-4974-A8C9-D0CBB4D471C2 @default.
- Q88739962 P2860 Q88739962-0E73564E-AE51-4156-8E4C-DC79F2868E19 @default.
- Q88739962 P2860 Q88739962-10CDBD85-7D92-408F-8631-E6465A08ABBA @default.
- Q88739962 P2860 Q88739962-17D660F0-2859-4A07-A7DF-6AB9437693EA @default.
- Q88739962 P2860 Q88739962-1E359561-D3FA-4532-BAE3-A347884D6DAB @default.
- Q88739962 P2860 Q88739962-292A0E64-E2C2-40A0-8999-6E3E012334B1 @default.
- Q88739962 P2860 Q88739962-34E3E370-7A7E-46EB-A040-B326C033551A @default.
- Q88739962 P2860 Q88739962-39C00091-4732-478C-AC75-C8322BD1CE23 @default.
- Q88739962 P2860 Q88739962-4A9AADCD-1187-41A2-BDB6-41C395FA89B5 @default.
- Q88739962 P2860 Q88739962-52078299-FC6E-4141-B6CF-2D5F6A195814 @default.
- Q88739962 P2860 Q88739962-5300CE02-3B44-45EA-BB3F-F3E78A926347 @default.
- Q88739962 P2860 Q88739962-5D1901D5-ADFB-48BF-94A5-E0D494111A0C @default.
- Q88739962 P2860 Q88739962-71CD3DD6-B041-41AD-A8C7-3B2A9366DBB1 @default.
- Q88739962 P2860 Q88739962-7257EF61-AC7E-4497-9654-CB485B8DDB9B @default.
- Q88739962 P2860 Q88739962-7F3DD48F-BC7C-4B9D-9646-4FDA2D63E664 @default.
- Q88739962 P2860 Q88739962-952F6ACA-DDCE-4E84-B71A-54303F4555BC @default.
- Q88739962 P2860 Q88739962-997B8512-14D2-43A0-8D1C-6E179591D5D8 @default.
- Q88739962 P2860 Q88739962-9C866B4A-C215-42F0-BC1D-620903CFE129 @default.
- Q88739962 P2860 Q88739962-A024CA46-22AD-46E8-8DB6-5FEC829153CF @default.
- Q88739962 P2860 Q88739962-A350E5B2-649F-4045-9FEC-51D30F3A4C65 @default.
- Q88739962 P2860 Q88739962-A5A12E62-8DE5-4E34-8AD3-E58FC472DC11 @default.
- Q88739962 P2860 Q88739962-A73A7EA2-95CA-475C-AA96-F30E9327264B @default.
- Q88739962 P2860 Q88739962-B0936CA5-9F3F-47BD-AB2C-4F247B9FD844 @default.
- Q88739962 P2860 Q88739962-B659BDF5-A2E7-493B-A6C1-82D9B1C55B15 @default.
- Q88739962 P2860 Q88739962-B9600905-5CDD-45A0-A588-194A0C7B37E0 @default.
- Q88739962 P2860 Q88739962-BC0BC354-3179-40DC-8FE3-6534EB5CF657 @default.
- Q88739962 P2860 Q88739962-D60498B3-2BB5-46CA-9EE4-1039A5B28343 @default.
- Q88739962 P2860 Q88739962-FFD3111D-2055-4C05-B4D1-95A405A94A81 @default.
- Q88739962 P304 Q88739962-BA4FC47A-C1E9-4AD0-BA1F-E04B8AB47F02 @default.
- Q88739962 P31 Q88739962-D028BBBD-CA7B-462C-81F5-3CFF407DDC14 @default.
- Q88739962 P356 Q88739962-31AC12F2-7711-4EDC-8D63-6A7DA5D68A55 @default.
- Q88739962 P433 Q88739962-46982C79-3F3F-4726-9B2C-99D61B11CDB8 @default.
- Q88739962 P478 Q88739962-8C9FC9A5-10A9-49AF-8CF3-A2D78D4F9133 @default.
- Q88739962 P577 Q88739962-F9DF7457-A513-48AE-8173-0AA6DD730192 @default.
- Q88739962 P698 Q88739962-25051C0E-365B-4A5B-BE29-BDC98FEAB948 @default.
- Q88739962 P921 Q88739962-FDCEEC37-D8DE-46ED-B551-E8B88CC51F31 @default.
- Q88739962 P932 Q88739962-2CB91152-9439-4A7D-9005-AF9809A5CCD9 @default.
- Q88739962 P356 1567201815666180518125839 @default.
- Q88739962 P698 29779479 @default.
- Q88739962 P1433 Q15745388 @default.
- Q88739962 P1476 "Optimizing Antitumor Efficacy and Adverse Effects of Pegylated Liposomal Doxorubicin by Scheduled Plasmapheresis: Impact of Timing and Dosing" @default.
- Q88739962 P2093 "Christine Contini" @default.
- Q88739962 P2093 "Dominik von Elverfeldt" @default.
- Q88739962 P2093 "Gerhard Putz" @default.
- Q88739962 P2093 "Karl Winkler" @default.
- Q88739962 P2093 "Michael M Hoffmann" @default.
- Q88739962 P2093 "Romeo Ngoune" @default.
- Q88739962 P2860 Q28266845 @default.
- Q88739962 P2860 Q28285226 @default.
- Q88739962 P2860 Q34410549 @default.
- Q88739962 P2860 Q35124674 @default.
- Q88739962 P2860 Q35218744 @default.
- Q88739962 P2860 Q36589023 @default.
- Q88739962 P2860 Q37935987 @default.
- Q88739962 P2860 Q38000876 @default.
- Q88739962 P2860 Q38089102 @default.
- Q88739962 P2860 Q38314457 @default.
- Q88739962 P2860 Q39005226 @default.
- Q88739962 P2860 Q39284144 @default.
- Q88739962 P2860 Q39569801 @default.
- Q88739962 P2860 Q40009949 @default.
- Q88739962 P2860 Q46136376 @default.
- Q88739962 P2860 Q46766432 @default.
- Q88739962 P2860 Q47830237 @default.
- Q88739962 P2860 Q50901184 @default.
- Q88739962 P2860 Q52937218 @default.
- Q88739962 P2860 Q55652029 @default.
- Q88739962 P2860 Q56453315 @default.
- Q88739962 P2860 Q57108785 @default.
- Q88739962 P2860 Q68000703 @default.